Melane Sampson, Author at BioTuesdays

Developments

FDA accepts Revelation’s IND for Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...

December 2, 2024

Developments

Elite launches generic hydrocodone and acetaminophen tables for pain management

Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...

December 2, 2024

Developments

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...

November 28, 2024

Developments

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...

November 27, 2024

Developments

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...

November 26, 2024

Developments

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...

November 26, 2024

Feature

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...

November 26, 2024

Developments

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

Ikonisys Group (Euronext Paris:ALIKO) announced that its subsidiary, Hospitex, has been awarded a public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in...

November 25, 2024

Developments

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

Enveric Biosciences (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile. EB-003 is a potential...

November 25, 2024

Developments

BioLineRx enters license agreement with Ayrmid for APHEXDA

BioLineRx (NASDAQ:BLRX; TASE:BLRX) and Ayrmid, the parent company of Gamida Cell, announced they have entered into a licensing agreement for motixafortide, commercially marketed in the U.S. as BioLineRx’s APHEXDA. The...

November 22, 2024

Author - Melane Sampson

FDA accepts Revelation’s IND for Gemini in CKD

Elite launches generic hydrocodone and acetaminophen tables for pain management

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

BioLineRx enters license agreement with Ayrmid for APHEXDA

General

More